Selected article for: "convalescent plasma and plasma treatment"
Author: Rodriguez, Zahidee; Shane, Andi L.; Verkerke, Hans; Lough, Christopher; Zimmerman, Matthew G.; Suthar, Mehul; Wrammert, Jens; MacDonald, Heather; Wolf, Michael; Clarke, Shanelle; Roback, John D.; Arthur, Connie M.; Stowell, Sean R.; Josephson, Cassandra D.
Title: COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
  • Cord-id: 2e2h5fg1
  • Document date: 2020_9_11
    • ID: 2e2h5fg1
    Snippet: COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.
    Document: COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and active infection: 1
    • absolute lymphocyte count and lung injury: 1, 2
    • absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • absolute lymphocyte count and lymphocyte increase: 1
    • absolute lymphocyte count and macrophage activation: 1
    • absolute lymphocyte count and macrophage activation syndrome: 1
    • acid testing and active infection: 1, 2, 3, 4
    • acid testing and acute lung injury: 1, 2
    • acid testing and lung injury: 1, 2, 3
    • acid testing and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acid testing and lymphocyte increase: 1, 2
    • active infection and acute lung injury: 1, 2, 3, 4, 5
    • active infection and adequate testing: 1
    • active infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active infection and lymphocyte count: 1, 2, 3
    • active infection and macrophage activation: 1, 2
    • active infection and macrophage activation syndrome: 1
    • acute lung injury and additional investigation: 1
    • acute lung injury and adequate testing: 1